GlycoMimetics Inc. (NASDAQ:GLYC)’s share price rose 5.9% during mid-day trading on Friday . The company traded as high as $7.82 and last traded at $7.68, with a volume of 59,355 shares. The stock had previously closed at $7.25.

GLYC has been the topic of a number of recent research reports. Canaccord Genuity restated a “buy” rating and issued a $12.00 price objective on shares of GlycoMimetics in a report on Wednesday, May 4th. Zacks Investment Research upgraded shares of GlycoMimetics from a “sell” rating to a “hold” rating in a report on Tuesday, May 3rd.

The firm has a 50 day moving average price of $7.47 and a 200 day moving average price of $6.10. The firm’s market cap is $152.28 million.

GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings results on Wednesday, May 4th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.07. On average, equities analysts expect that GlycoMimetics Inc. will post ($1.82) EPS for the current year.

In related news, CMO Helen M. Thackray sold 22,000 shares of GlycoMimetics stock in a transaction dated Wednesday, July 6th. The shares were sold at an average price of $7.00, for a total transaction of $154,000.00. Following the completion of the transaction, the chief marketing officer now directly owns 179,547 shares of the company’s stock, valued at approximately $1,256,829. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.